Micra AV Registry Reinforces Medtronic’s Leadless Pace

Medtronic (MDT) announced an update on their ongoing clinical study.

Micra AV Post-Approval Registry shows Medtronic tracking long-term performance of its leadless pacemaker to confirm real-world safety and atrioventricular synchrony benefits for bradycardia patients.

The registry follows the Micra AV Transcatheter Pacing System, a catheter-delivered mini pacemaker positioned inside the right ventricle to maintain synchronized pacing without leads.

This prospective cohort registry allocates no randomization, uses routine-care observation, and focuses on surveillance rather than treatment comparison, keeping procedures unblinded.

Key dates: enrollment began in January 2020, primary data collection concluded in 2023, final completion is recorded as 2026, and the latest update hit the registry on February 2, 2026, signaling fresh validation.

Medtronic investors may read the completed registry as reinforcement of the Micra line’s commercial durability, while rivals like Abbott continue to chase leadless pacing share; steady safety data can support valuation resilience.

This study remains documented as completed with updates available through the ClinicalTrials portal.

To learn more about MDT’s potential, visit the Medtronic drug pipeline page.